FontsA A
ContrastA A
Newsletter sign-up [mc4wp_form id="1441"]
  • FAQ
  • Downloads
  • Home
x

bbmri-eric website

  • Find samples and data
  • About
    • Member States & National Nodes
    • Governance
    • Stakeholder Forum
    • Expert Centres
    • Staff
    • Jobs
    • Intranet
    • BBMRI-ERIC Podcast
  • Services & Support
    • Directory
    • Sample/Data Locator
    • BBMRI-ERIC Federated Platform
    • MIABIS
    • MIABIS draft2
    • Access Policies
    • About the Sample/Data Negotiator
    • Colorectal Cancer Cohort
    • Quality Management
    • ELSI Services & Research
    • GDPR Code of Conduct
    • COVID-19 Research
      • List COVID-Ready Samples and Data on our Directory
  • EU Grants
    • B1MG
    • BigPicture
    • BY-COVID
    • canSERV
    • CETOCOEN Excellence TEAMING Phase II
    • CINECA
    • ConcePTION
    • CY-BIOBANK
    • DIAMONDS
    • EDIReX
    • EHDS2 Pilot
    • EJP RD
    • EOSC Future
    • EOSC-Life
    • EPND
    • ERIC Forum
    • EUCAN-Connect
    • EuCanImage
    • euCanSHare
    • HealthyCloud
    • IC2PerMed
    • INTERVENE
    • ISIDORe
    • PROPHET
    • RABBIT 2
    • RI-VIS
    • SPIDIA4P
    • Completed Projects
  • News & Events
    • News
    • Events
  • Contact
  • BBMRI-ERIC Task Forces and Working Groups
Home  - News & Events Overview  -  ARTICLE IN “THE LANCET Oncology”  
  • Find samples and data
  • About
    • Member States & National Nodes
    • Governance
    • Stakeholder Forum
    • Expert Centres
    • Staff
    • Jobs
    • Intranet
    • BBMRI-ERIC Podcast
  • Services & Support
    • Directory
    • Sample/Data Locator
    • BBMRI-ERIC Federated Platform
    • MIABIS
    • MIABIS draft2
    • Access Policies
    • About the Sample/Data Negotiator
    • Colorectal Cancer Cohort
    • Quality Management
    • ELSI Services & Research
    • GDPR Code of Conduct
    • COVID-19 Research
      • List COVID-Ready Samples and Data on our Directory
  • EU Grants
    • B1MG
    • BigPicture
    • BY-COVID
    • canSERV
    • CETOCOEN Excellence TEAMING Phase II
    • CINECA
    • ConcePTION
    • CY-BIOBANK
    • DIAMONDS
    • EDIReX
    • EHDS2 Pilot
    • EJP RD
    • EOSC Future
    • EOSC-Life
    • EPND
    • ERIC Forum
    • EUCAN-Connect
    • EuCanImage
    • euCanSHare
    • HealthyCloud
    • IC2PerMed
    • INTERVENE
    • ISIDORe
    • PROPHET
    • RABBIT 2
    • RI-VIS
    • SPIDIA4P
    • Completed Projects
  • News & Events
    • News
    • Events
  • Contact
  • BBMRI-ERIC Task Forces and Working Groups
  • FAQ
  • Downloads
  • Home

I am looking for information as

Researcher

  • Looking for biobanks
  • Looking for samples & data
  • Looking for trusted partners (Expert Centres)
  • Looking for ELSI guidance
  • Looking for scientific collaboration
  • Looking for advice on standardisation
  • Looking for info on projects
  • Looking for scientific publications

Industry

  • Looking for biobanks
  • Looking for trusted partners (Expert Centres)
  • Looking for samples & data
  • Looking for advice on standardisation
  • Looking for scientific collaboration

Patient

  • Working with patient organisations
  • About ethics, rights & societal issues
  • Looking for general information on BBMRI-ERIC
  • About our scientific collaboration

Citizen

  • FAQs (what is a sample, what is a biobank)
  • Looking for biobanks in your country

Member States

  • Looking for information on your country
  • How to become a Member
  • Looking for reports and statutes
  • Looking for samples & data

PROSTATE CANCER SCREENING IN MEN AGED 50–69 YEARS (STHLM3): A PROSPECTIVE POPULATION-BASED DIAGNOSTIC STUDY

Summary

Background

The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone.

Methods

The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50–69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency. Men with prostate cancer at enrolment were excluded from the study. The predefined STHLM3 model (a combination of plasma protein biomarkers [PSA, free PSA, intact PSA, hK2, MSMB, MIC1], genetic polymorphisms [232 SNPs], and clinical variables [age, family, history, previous prostate biopsy, prostate exam]), and PSA concentration were both tested in all participants enrolled. The primary aim was to increase the specificity compared with PSA without decreasing the sensitivity to diagnose high-risk prostate cancer. The primary outcomes were number of detected high-risk cancers (sensitivity) and the number of performed prostate biopsies (specificity). The STHLM3 training cohort was used to train the STHLM3 model, which was prospectively tested in the STHLM3 validation cohort. Logistic regression was used to test for associations between biomarkers and clinical variables and prostate cancer with a Gleason score of at least 7. This study is registered with ISCRTN.com, number ISRCTN84445406.

Findings

The STHLM3 model performed significantly better than PSA alone for detection of cancers with a Gleason score of at least 7 (p<0·0001), the area under the curve was 0·56 (95% CI 0·55–0·60) with PSA alone and 0·74 (95% CI 0·72–0·75) with the STHLM3 model. All variables used in the STHLM3 model were significantly associated with prostate cancers with a Gleason score of at least 7 (p<0·05) in a multiple logistic regression model. At the same level of sensitivity as the PSA test using a cutoff of ≥3 ng/mL to diagnose high risk prostate cancer, use of the STHLM3 model could reduce the number of biopsies by 32% (95% CI 24–39) and could avoid 44% (35–54) of benign biopsies.

Interpretation

The STHLM3 model could reduce unnecessary biopsies without compromising the ability to diagnose prostate cancer with a Gleason score of at least 7, and could be a step towards personalised risk-based prostate cancer diagnostic programmes.

Funding

Stockholm County Council (Stockholms Läns Landsting).

 

Find the whole article here!

Show me:

  • ALL News & Events
  • Research
  • Press Releases
  • Industry
  • Quality
  • Events
  • Scientific Publications
  • News
  • Vacancies
  • ELSI
  • Projects
  • Webinars
  • Policy

The website was co-funded within ADOPT BBMRI-ERIC, a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676550.

Neue Stiftingtalstrasse 2/B/6
8010 Graz, Austria

Phone: +43 316 34 99 170
Fax: +43 316 34 99 17-99
Mail: contact@bbmri-eric.eu

 

 

Favourites

  • About us
  • News & Events
  • Publications

Quicklinks

  • Directory
  • Negotiator
  • National Nodes

How to find us

Newsletter sign-up

[mc4wp_form id="1441"]

Follow us

rss feed
(c) BBMRI-ERIC® - Legal Notice - Privacy Notice
TOP
Website by Werbeagentur Rubikon
We use cookies to analyse the traffic on our websites. All personal data is anonymized and not shared with third parties! Click here for more information.
Accept